{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T16:05:30Z","timestamp":1759939530782},"reference-count":80,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2016,10,12]],"date-time":"2016-10-12T00:00:00Z","timestamp":1476230400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Hematol Malig Rep"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1007\/s11899-016-0349-7","type":"journal-article","created":{"date-parts":[[2016,10,12]],"date-time":"2016-10-12T21:44:10Z","timestamp":1476308650000},"page":"545-552","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Antibody-Based Treatment of Acute Myeloid Leukemia"],"prefix":"10.1007","volume":"11","author":[{"given":"Phillip M.","family":"Garfin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric J.","family":"Feldman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,10,12]]},"reference":[{"issue":"2","key":"349_CR1","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1053\/j.seminhematol.2008.02.001","volume":"45","author":"BA Christian","year":"2008","unstructured":"Christian BA, Lin TS. Antibody therapy for chronic lymphocytic leukemia. Semin Hematol. 2008;45(2):95\u2013103.","journal-title":"Semin Hematol"},{"issue":"6","key":"349_CR2","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1182\/blood.V90.6.2188","volume":"90","author":"DG Maloney","year":"1997","unstructured":"Maloney DG et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood. 1997;90(6):2188\u201395.","journal-title":"Blood"},{"issue":"1","key":"349_CR3","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S1470-2045(14)71170-2","volume":"16","author":"MS Topp","year":"2015","unstructured":"Topp MS et al. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. Lancet Oncol. 2015;16(1):57\u201366.","journal-title":"Lancet Oncol"},{"key":"349_CR4","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2014.39","volume":"4","author":"A Ehninger","year":"2014","unstructured":"Ehninger A et al. Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemia. Blood Cancer J. 2014;4, e218.","journal-title":"Blood Cancer J"},{"issue":"1","key":"349_CR5","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s11899-011-0103-0","volume":"7","author":"JG Jurcic","year":"2012","unstructured":"Jurcic JG. What happened to anti-CD33 therapy for acute myeloid leukemia? Curr Hematol Malig Rep. 2012;7(1):65\u201373.","journal-title":"Curr Hematol Malig Rep"},{"issue":"2","key":"349_CR6","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1053\/shem.2001.21924","volume":"38","author":"EG Weir","year":"2001","unstructured":"Weir EG, Borowitz MJ. Flow cytometry in the diagnosis of acute leukemia. Semin Hematol. 2001;38(2):124\u201338.","journal-title":"Semin Hematol"},{"issue":"5","key":"349_CR7","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1136\/jcp.51.5.364","volume":"51","author":"L Ginaldi","year":"1998","unstructured":"Ginaldi L et al. Levels of expression of CD19 and CD20 in chronic B cell leukaemias. J Clin Pathol. 1998;51(5):364\u20139.","journal-title":"J Clin Pathol"},{"issue":"4785","key":"349_CR8","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1126\/science.3798106","volume":"235","author":"DJ Slamon","year":"1987","unstructured":"Slamon DJ et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2\/neu oncogene. Science. 1987;235(4785):177\u201382.","journal-title":"Science"},{"issue":"4","key":"349_CR9","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1309\/1WMW-CMXX-4WN4-T55U","volume":"118","author":"I Jilani","year":"2002","unstructured":"Jilani I et al. Differences in CD33 intensity between various myeloid neoplasms. Am J Clin Pathol. 2002;118(4):560\u20136.","journal-title":"Am J Clin Pathol"},{"issue":"2","key":"349_CR10","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0145-2126(97)00158-6","volume":"22","author":"L Ginaldi","year":"1998","unstructured":"Ginaldi L et al. Levels of expression of CD52 in normal and leukemic B and T cells: correlation with in vivo therapeutic responses to Campath-1H. Leuk Res. 1998;22(2):185\u201391.","journal-title":"Leuk Res"},{"issue":"12","key":"349_CR11","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1182\/blood.V98.12.3383","volume":"98","author":"J Golay","year":"2001","unstructured":"Golay J et al. CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59. Blood. 2001;98(12):3383\u20139.","journal-title":"Blood"},{"issue":"26","key":"349_CR12","doi-asserted-by":"crossref","first-page":"6198","DOI":"10.1182\/blood-2011-11-325050","volume":"119","author":"RB Walter","year":"2012","unstructured":"Walter RB et al. Acute myeloid leukemia stem cells and CD33-targeted immunotherapy. Blood. 2012;119(26):6198\u2013208.","journal-title":"Blood"},{"issue":"2","key":"349_CR13","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1038\/sj.leu.2402803","volume":"17","author":"E Feldman","year":"2003","unstructured":"Feldman E et al. Treatment of relapsed or refractory acute myeloid leukemia with humanized anti-CD33 monoclonal antibody HuM195. Leukemia. 2003;17(2):314\u20138.","journal-title":"Leukemia"},{"issue":"2","key":"349_CR14","first-page":"372","volume":"6","author":"JG Jurcic","year":"2000","unstructured":"Jurcic JG et al. Molecular remission induction with retinoic acid and anti-CD33 monoclonal antibody HuM195 in acute promyelocytic leukemia. Clin Cancer Res. 2000;6(2):372\u201380.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"349_CR15","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3324\/haematol.2012.066613","volume":"98","author":"MA Sekeres","year":"2013","unstructured":"Sekeres MA et al. Randomized phase IIb study of low-dose cytarabine and lintuzumab versus low-dose cytarabine and placebo in older adults with untreated acute myeloid leukemia. Haematologica. 2013;98(1):119\u201328.","journal-title":"Haematologica"},{"issue":"22","key":"349_CR16","doi-asserted-by":"crossref","first-page":"3393","DOI":"10.1182\/blood-2015-02-567453","volume":"125","author":"P Armand","year":"2015","unstructured":"Armand P. Immune checkpoint blockade in hematologic malignancies. Blood. 2015;125(22):3393\u2013400.","journal-title":"Blood"},{"issue":"26","key":"349_CR17","doi-asserted-by":"crossref","first-page":"7007","DOI":"10.1182\/blood-2011-02-337725","volume":"117","author":"M Buyse","year":"2011","unstructured":"Buyse M et al. Individual patient data meta-analysis of randomized trials evaluating IL-2 monotherapy as remission maintenance therapy in acute myeloid leukemia. Blood. 2011;117(26):7007\u201313.","journal-title":"Blood"},{"issue":"11","key":"349_CR18","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1016\/j.bbmt.2014.07.010","volume":"20","author":"A Takami","year":"2014","unstructured":"Takami A et al. Donor lymphocyte infusion for the treatment of relapsed acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation: a retrospective analysis by the Adult Acute Myeloid Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2014;20(11):1785\u201390.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"349_CR19","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1097\/00001622-200111000-00016","volume":"13","author":"EL Sievers","year":"2001","unstructured":"Sievers EL, Linenberger M. Mylotarg: antibody-targeted chemotherapy comes of age. Curr Opin Oncol. 2001;13(6):522\u20137.","journal-title":"Curr Opin Oncol"},{"issue":"13","key":"349_CR20","doi-asserted-by":"crossref","first-page":"3244","DOI":"10.1200\/JCO.2001.19.13.3244","volume":"19","author":"EL Sievers","year":"2001","unstructured":"Sievers EL et al. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol. 2001;19(13):3244\u201354.","journal-title":"J Clin Oncol"},{"issue":"7","key":"349_CR21","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1002\/cncr.21326","volume":"104","author":"RA Larson","year":"2005","unstructured":"Larson RA et al. Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence. Cancer. 2005;104(7):1442\u201352.","journal-title":"Cancer"},{"issue":"9","key":"349_CR22","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/S1470-2045(14)70281-5","volume":"15","author":"RK Hills","year":"2014","unstructured":"Hills RK et al. Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials. Lancet Oncol. 2014;15(9):986\u201396.","journal-title":"Lancet Oncol"},{"issue":"24","key":"349_CR23","doi-asserted-by":"crossref","first-page":"4854","DOI":"10.1182\/blood-2013-01-466706","volume":"121","author":"SH Petersdorf","year":"2013","unstructured":"Petersdorf SH et al. A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia. Blood. 2013;121(24):4854\u201360.","journal-title":"Blood"},{"issue":"3","key":"349_CR24","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1111\/bjh.12528","volume":"163","author":"MA Kharfan-Dabaja","year":"2013","unstructured":"Kharfan-Dabaja MA et al. Gemtuzumab ozogamicin for treatment of newly diagnosed acute myeloid leukaemia: a systematic review and meta-analysis. Br J Haematol. 2013;163(3):315\u201325.","journal-title":"Br J Haematol"},{"issue":"24","key":"349_CR25","doi-asserted-by":"crossref","first-page":"4838","DOI":"10.1182\/blood-2013-03-490482","volume":"121","author":"JM Rowe","year":"2013","unstructured":"Rowe JM, Lowenberg B. Gemtuzumab ozogamicin in acute myeloid leukemia: a remarkable saga about an active drug. Blood. 2013;121(24):4838\u201341.","journal-title":"Blood"},{"issue":"9825","key":"349_CR26","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1016\/S0140-6736(12)60485-1","volume":"379","author":"S Castaigne","year":"2012","unstructured":"Castaigne S et al. Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. Lancet. 2012;379(9825):1508\u201316.","journal-title":"Lancet"},{"issue":"11","key":"349_CR27","doi-asserted-by":"crossref","first-page":"3678","DOI":"10.1182\/blood.V93.11.3678","volume":"93","author":"EL Sievers","year":"1999","unstructured":"Sievers EL et al. Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: a phase I study of an anti-CD33 calicheamicin immunoconjugate. Blood. 1999;93(11):3678\u201384.","journal-title":"Blood"},{"issue":"2","key":"349_CR28","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1002\/1097-0142(20010715)92:2<406::AID-CNCR1336>3.0.CO;2-U","volume":"92","author":"FJ Giles","year":"2001","unstructured":"Giles FJ et al. Mylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation. Cancer. 2001;92(2):406\u201313.","journal-title":"Cancer"},{"issue":"5","key":"349_CR29","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1182\/blood-2003-01-0255","volume":"102","author":"M Wadleigh","year":"2003","unstructured":"Wadleigh M et al. Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation. Blood. 2003;102(5):1578\u201382.","journal-title":"Blood"},{"issue":"1","key":"349_CR30","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/sj.bmt.1703602","volume":"30","author":"AD Cohen","year":"2002","unstructured":"Cohen AD et al. Gemtuzumab ozogamicin (Mylotarg) monotherapy for relapsed AML after hematopoietic stem cell transplant: efficacy and incidence of hepatic veno-occlusive disease. Bone Marrow Transplant. 2002;30(1):23\u20138.","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"349_CR31","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.leukres.2006.07.005","volume":"31","author":"JM McKoy","year":"2007","unstructured":"McKoy JM et al. Gemtuzumab ozogamicin-associated sinusoidal obstructive syndrome (SOS): an overview from the research on adverse drug events and reports (RADAR) project. Leuk Res. 2007;31(5):599\u2013604.","journal-title":"Leuk Res"},{"issue":"7","key":"349_CR32","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1182\/blood.V99.7.2310","volume":"99","author":"P Rajvanshi","year":"2002","unstructured":"Rajvanshi P et al. Hepatic sinusoidal obstruction after gemtuzumab ozogamicin (Mylotarg) therapy. Blood. 2002;99(7):2310\u20134.","journal-title":"Blood"},{"issue":"9","key":"349_CR33","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1200\/JCO.2015.64.0060","volume":"34","author":"S Amadori","year":"2016","unstructured":"Amadori S et al. Gemtuzumab Ozogamicin Versus Best Supportive Care in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Unsuitable for Intensive Chemotherapy: Results of the Randomized Phase III EORTC-GIMEMA AML-19 Trial. J Clin Oncol. 2016;34(9):972\u20139.","journal-title":"J Clin Oncol"},{"issue":"Suppl 1","key":"349_CR34","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.3816\/CLM.2002.s.007","volume":"2","author":"GB McDonald","year":"2002","unstructured":"McDonald GB. Management of hepatic sinusoidal obstruction syndrome following treatment with gemtuzumab ozogamicin (Mylotarg). Clin Lymphoma. 2002;2 Suppl 1:S35\u20139.","journal-title":"Clin Lymphoma"},{"key":"349_CR35","doi-asserted-by":"crossref","unstructured":"Kantarjian HM et al., Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia. N Engl J Med. 2016.","DOI":"10.1056\/NEJMoa1509277"},{"issue":"2","key":"349_CR36","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s00262-012-1369-3","volume":"62","author":"B Gorovits","year":"2013","unstructured":"Gorovits B, Krinos-Fiorotti C. Proposed mechanism of off-target toxicity for antibody-drug conjugates driven by mannose receptor uptake. Cancer Immunol Immunother. 2013;62(2):217\u201323.","journal-title":"Cancer Immunol Immunother"},{"issue":"6","key":"349_CR37","first-page":"1490","volume":"7","author":"PF Bross","year":"2001","unstructured":"Bross PF et al. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin Cancer Res. 2001;7(6):1490\u20136.","journal-title":"Clin Cancer Res"},{"issue":"10","key":"349_CR38","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1080\/1042819021000016078","volume":"43","author":"GJ Roboz","year":"2002","unstructured":"Roboz GJ et al. Efficacy and safety of gemtuzumab ozogamicin in patients with poor-prognosis acute myeloid leukemia. Leuk Lymphoma. 2002;43(10):1951\u20135.","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"349_CR39","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1021\/bc700321z","volume":"19","author":"I Hollander","year":"2008","unstructured":"Hollander I, Kunz A, Hamann PR. Selection of reaction additives used in the preparation of monomeric antibody-calicheamicin conjugates. Bioconjug Chem. 2008;19(1):358\u201361.","journal-title":"Bioconjug Chem"},{"issue":"2","key":"349_CR40","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1038\/sj.leu.2403205","volume":"18","author":"I Jedema","year":"2004","unstructured":"Jedema I et al. Internalization and cell cycle-dependent killing of leukemic cells by Gemtuzumab Ozogamicin: rationale for efficacy in CD33-negative malignancies with endocytic capacity. Leukemia. 2004;18(2):316\u201325.","journal-title":"Leukemia"},{"issue":"6","key":"349_CR41","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.3892\/ijo_00000638","volume":"36","author":"M Cianfriglia","year":"2010","unstructured":"Cianfriglia M et al. Multidrug transporter proteins and cellular factors involved in free and mAb linked calicheamicin-gamma1 (gentuzumab ozogamicin, GO) resistance and in the selection of GO resistant variants of the HL60 AML cell line. Int J Oncol. 2010;36(6):1513\u201320.","journal-title":"Int J Oncol"},{"issue":"8","key":"349_CR42","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1182\/blood-2013-03-491506","volume":"122","author":"MS Kung Sutherland","year":"2013","unstructured":"Kung Sutherland MS et al. SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML. Blood. 2013;122(8):1455\u201363.","journal-title":"Blood"},{"key":"349_CR43","doi-asserted-by":"crossref","unstructured":"Fathi AT et al. SGN-CD33A Plus Hypomethylating Agents: A Novel, Well-Tolerated Regimen with High Remission Rate in Frontline Unfit AML. in American Society for Hematology. 2015. Orland, Florida.","DOI":"10.1182\/blood.V126.23.454.454"},{"issue":"23","key":"349_CR44","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/blood.V126.23.1.1","volume":"126","author":"AS Stein","year":"2015","unstructured":"Stein AS et al. A phase 1 Trial of SGN-CD33A As Monotherapy in Patients with CD33-Positive Acute Myeloid Leukemia (AML). Blood Cancer J. 2015;126(23):1.","journal-title":"Blood Cancer J"},{"key":"349_CR45","unstructured":"Seattle Genetics, Inc. Vadastuximab Talirine (SGN-CD33A; 33A) COmbined with Azacitidine or Decitabine in Older Patients with Newly Diagnosed Acute Myeloid Leukemia (CASCADE). In ClinicalTrials.gov [Internet]. 2016. 20160804]; Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT0278590 ."},{"issue":"Suppl 4","key":"349_CR46","doi-asserted-by":"crossref","first-page":"S37","DOI":"10.1080\/10428190310001616944","volume":"44","author":"A Hagenbeek","year":"2003","unstructured":"Hagenbeek A. Radioimmunotherapy for NHL: experience of 90Y-ibritumomab tiuxetan in clinical practice. Leuk Lymphoma. 2003;44 Suppl 4:S37\u201347.","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"349_CR47","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/sj.bmt.1704201","volume":"32","author":"JM Burke","year":"2003","unstructured":"Burke JM et al. Cytoreduction with iodine-131-anti-CD33 antibodies before bone marrow transplantation for advanced myeloid leukemias. Bone Marrow Transplant. 2003;32(6):549\u201356.","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"349_CR48","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1111\/j.1365-2141.2005.05663.x","volume":"130","author":"M Ringhoffer","year":"2005","unstructured":"Ringhoffer M et al. 188Re or 90Y-labelled anti-CD66 antibody as part of a dose-reduced conditioning regimen for patients with acute leukaemia or myelodysplastic syndrome over the age of 55: results of a phase I-II study. Br J Haematol. 2005;130(4):604\u201313.","journal-title":"Br J Haematol"},{"issue":"5","key":"349_CR49","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1182\/blood-2005-06-2317","volume":"107","author":"JM Pagel","year":"2006","unstructured":"Pagel JM et al. 131I-anti-CD45 antibody plus busulfan and cyclophosphamide before allogeneic hematopoietic cell transplantation for treatment of acute myeloid leukemia in first remission. Blood. 2006;107(5):2184\u201391.","journal-title":"Blood"},{"issue":"14","key":"349_CR50","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1002\/cncr.30031","volume":"122","author":"HM Kantarjian","year":"2016","unstructured":"Kantarjian HM et al. Blinatumomab treatment of older adults with relapsed\/refractory B-precursor acute lymphoblastic leukemia: Results from 2 phase 2 studies. Cancer. 2016;122(14):2178\u201385.","journal-title":"Cancer"},{"issue":"4","key":"349_CR51","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1182\/blood-2013-09-527044","volume":"123","author":"GS Laszlo","year":"2014","unstructured":"Laszlo GS et al. Cellular determinants for preclinical activity of a novel CD33\/CD3 bispecific T-cell engager (BiTE) antibody, AMG 330, against human AML. Blood. 2014;123(4):554\u201361.","journal-title":"Blood"},{"issue":"6","key":"349_CR52","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1158\/1535-7163.MCT-13-0956","volume":"13","author":"M Friedrich","year":"2014","unstructured":"Friedrich M et al. Preclinical characterization of AMG 330, a CD3\/CD33-bispecific T-cell-engaging antibody with potential for treatment of acute myelogenous leukemia. Mol Cancer Ther. 2014;13(6):1549\u201357.","journal-title":"Mol Cancer Ther"},{"issue":"26","key":"349_CR53","doi-asserted-by":"crossref","first-page":"5154","DOI":"10.1182\/blood-2013-02-485623","volume":"121","author":"DT Teachey","year":"2013","unstructured":"Teachey DT et al. Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy. Blood. 2013;121(26):5154\u20137.","journal-title":"Blood"},{"issue":"12","key":"349_CR54","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1182\/blood-2011-10-384388","volume":"119","author":"JN Kochenderfer","year":"2012","unstructured":"Kochenderfer JN et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood. 2012;119(12):2709\u201320.","journal-title":"Blood"},{"issue":"3","key":"349_CR55","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1182\/blood-2004-07-2784","volume":"105","author":"RB Walter","year":"2005","unstructured":"Walter RB et al. Influence of CD33 expression levels and ITIM-dependent internalization on gemtuzumab ozogamicin-induced cytotoxicity. Blood. 2005;105(3):1295\u2013302.","journal-title":"Blood"},{"issue":"2","key":"349_CR56","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/sj.leu.2403598","volume":"19","author":"ML Linenberger","year":"2005","unstructured":"Linenberger ML. CD33-directed therapy with gemtuzumab ozogamicin in acute myeloid leukemia: progress in understanding cytotoxicity and potential mechanisms of drug resistance. Leukemia. 2005;19(2):176\u201382.","journal-title":"Leukemia"},{"issue":"32","key":"349_CR57","doi-asserted-by":"crossref","first-page":"5192","DOI":"10.1200\/JCO.2007.15.9764","volume":"26","author":"P Chevallier","year":"2008","unstructured":"Chevallier P et al. Long-term disease-free survival after gemtuzumab, intermediate-dose cytarabine, and mitoxantrone in patients with CD33(+) primary resistant or relapsed acute myeloid leukemia. J Clin Oncol. 2008;26(32):5192\u20137.","journal-title":"J Clin Oncol"},{"issue":"17","key":"349_CR58","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1182\/blood-2016-01-689976","volume":"127","author":"G Olombel","year":"2016","unstructured":"Olombel G et al. The level of blast CD33 expression positively impacts the effect of gemtuzumab ozogamicin in patients with acute myeloid leukemia. Blood. 2016;127(17):2157\u201360.","journal-title":"Blood"},{"issue":"16","key":"349_CR59","doi-asserted-by":"crossref","first-page":"3705","DOI":"10.1182\/blood-2011-12-398370","volume":"119","author":"JA Pollard","year":"2012","unstructured":"Pollard JA et al. Correlation of CD33 expression level with disease characteristics and response to gemtuzumab ozogamicin containing chemotherapy in childhood AML. Blood. 2012;119(16):3705\u201311.","journal-title":"Blood"},{"issue":"6","key":"349_CR60","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1158\/1078-0432.CCR-12-3115","volume":"19","author":"L Mortland","year":"2013","unstructured":"Mortland L et al. Clinical significance of CD33 nonsynonymous single-nucleotide polymorphisms in pediatric patients with acute myeloid leukemia treated with gemtuzumab-ozogamicin-containing chemotherapy. Clin Cancer Res. 2013;19(6):1620\u20137.","journal-title":"Clin Cancer Res"},{"key":"349_CR61","doi-asserted-by":"crossref","unstructured":"Laszlo GS et al. Expression and functional characterization of CD33 transcript variants in human acute myeloid leukemia. Oncotarget. 2016.","DOI":"10.18632\/oncotarget.9674"},{"issue":"2","key":"349_CR62","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1177\/107327480401100216","volume":"11","author":"ML Guzman","year":"2004","unstructured":"Guzman ML, Jordan CT. Considerations for targeting malignant stem cells in leukemia. Cancer Control. 2004;11(2):97\u2013104.","journal-title":"Cancer Control"},{"issue":"7","key":"349_CR63","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1038\/nm0797-730","volume":"3","author":"D Bonnet","year":"1997","unstructured":"Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med. 1997;3(7):730\u20137.","journal-title":"Nat Med"},{"issue":"9","key":"349_CR64","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0107587","volume":"9","author":"M Terwijn","year":"2014","unstructured":"Terwijn M et al. Leukemic stem cell frequency: a strong biomarker for clinical outcome in acute myeloid leukemia. PLoS ONE. 2014;9(9), e107587.","journal-title":"PLoS ONE"},{"issue":"2","key":"349_CR65","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/sj.leu.2403224","volume":"18","author":"U Testa","year":"2004","unstructured":"Testa U et al. Interleukin-3 receptor in acute leukemia. Leukemia. 2004;18(2):219\u201326.","journal-title":"Leukemia"},{"issue":"8","key":"349_CR66","doi-asserted-by":"crossref","first-page":"2980","DOI":"10.1182\/blood-2002-03-0852","volume":"100","author":"U Testa","year":"2002","unstructured":"Testa U et al. Elevated expression of IL-3Ralpha in acute myelogenous leukemia is associated with enhanced blast proliferation, increased cellularity, and poor prognosis. Blood. 2002;100(8):2980\u20138.","journal-title":"Blood"},{"issue":"10","key":"349_CR67","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1038\/sj.leu.2401903","volume":"14","author":"CT Jordan","year":"2000","unstructured":"Jordan CT et al. The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells. Leukemia. 2000;14(10):1777\u201384.","journal-title":"Leukemia"},{"issue":"12","key":"349_CR68","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.3324\/haematol.2011.047894","volume":"96","author":"F Vergez","year":"2011","unstructured":"Vergez F et al. High levels of CD34+CD38low\/-CD123+ blasts are predictive of an adverse outcome in acute myeloid leukemia: a Groupe Ouest-Est des Leucemies Aigues et Maladies du Sang (GOELAMS) study. Haematologica. 2011;96(12):1792\u20138.","journal-title":"Haematologica"},{"issue":"4","key":"349_CR69","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.bcmd.2015.07.015","volume":"55","author":"E Pelosi","year":"2015","unstructured":"Pelosi E, Castelli G, Testa U. Targeting LSCs through membrane antigens selectively or preferentially expressed on these cells. Blood Cells Mol Dis. 2015;55(4):336\u201346.","journal-title":"Blood Cells Mol Dis"},{"issue":"11","key":"349_CR70","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1038\/leu.2014.128","volume":"28","author":"SJ Busfield","year":"2014","unstructured":"Busfield SJ et al. Targeting of acute myeloid leukemia in vitro and in vivo with an anti-CD123 mAb engineered for optimal ADCC. Leukemia. 2014;28(11):2213\u201321.","journal-title":"Leukemia"},{"issue":"1","key":"349_CR71","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.stem.2009.04.018","volume":"5","author":"L Jin","year":"2009","unstructured":"Jin L et al. Monoclonal antibody-mediated targeting of CD123, IL-3 receptor alpha chain, eliminates human acute myeloid leukemic stem cells. Cell Stem Cell. 2009;5(1):31\u201342.","journal-title":"Cell Stem Cell"},{"key":"349_CR72","unstructured":"Smith BD et al. First-in Man, Phase 1 Study of CSL362 (Anti-IL3Ralpha\/Anti-CD123 Monoclonal Antibody) in Patients with CD123+ Acute Myeloid Leukemia (AML) in CR at High Risk for Early Relapse, in American Society of Hematology. 2014, American Society of Hematology: San Francisco, CA. p. 120."},{"key":"349_CR73","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1182\/blood.V126.23.330.330","volume":"126","author":"MS Kung Sutherland","year":"2015","unstructured":"Kung Sutherland MS et al. SGN-CD123A, a Pyrrolobenzodiazepine Dimer linked Anti-CD123 Antibody Drug Conjugate, Demonstrates Effective ANti-Leukemic Activity in Multiple Preclinical Models of AML. Blood. 2015;126:330.","journal-title":"Blood"},{"key":"349_CR74","unstructured":"Kovtun Y et al. ANnovel antibody drug conjugate of a CD123-targeting antibody with a potent DNA-Alkylator is highly active in preclinical models of AML with poor prognosis. EHA Learning Center. 2016: p. 135339."},{"key":"349_CR75","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1182\/blood.V122.21.360.360","volume":"122","author":"J Ritchey","year":"2013","unstructured":"Ritchey J et al. Targeting CD123 in Leukemic Stem Cells Using Dual Affinity Re-Targeting Molecults (DARTs(R)). Blood Cancer J. 2013;122:360.","journal-title":"Blood Cancer J"},{"issue":"22","key":"349_CR76","doi-asserted-by":"crossref","first-page":"8443","DOI":"10.1158\/0008-5472.CAN-04-1659","volume":"64","author":"AB Bakker","year":"2004","unstructured":"Bakker AB et al. C-type lectin-like molecule-1: a novel myeloid cell surface marker associated with acute myeloid leukemia. Cancer Res. 2004;64(22):8443\u201350.","journal-title":"Cancer Res"},{"issue":"37","key":"349_CR77","doi-asserted-by":"crossref","first-page":"9841","DOI":"10.1002\/anie.201405353","volume":"53","author":"H Lu","year":"2014","unstructured":"Lu H et al. Targeting human C-type lectin-like molecule-1 (CLL1) with a bispecific antibody for immunotherapy of acute myeloid leukemia. Angew Chem Int Ed Engl. 2014;53(37):9841\u20135.","journal-title":"Angew Chem Int Ed Engl"},{"issue":"9","key":"349_CR78","volume":"10","author":"J Liu","year":"2015","unstructured":"Liu J et al. Pre-Clinical Development of a Humanized Anti-CD47 Antibody with Anti-Cancer Therapeutic Potential. PLoS ONE. 2015;10(9), e0137345.","journal-title":"PLoS ONE"},{"issue":"1","key":"349_CR79","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1517\/14728222.2014.960843","volume":"19","author":"H Konig","year":"2015","unstructured":"Konig H, Levis M. Targeting FLT3 to treat leukemia. Expert Opin Ther Targets. 2015;19(1):37\u201354.","journal-title":"Expert Opin Ther Targets"},{"issue":"4","key":"349_CR80","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.blre.2016.02.001","volume":"30","author":"D Shafer","year":"2016","unstructured":"Shafer D, Grant S. Update on rational targeted therapy in AML. Blood Rev. 2016;30(4):275\u201383.","journal-title":"Blood Rev"}],"container-title":["Current Hematologic Malignancy Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-016-0349-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11899-016-0349-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-016-0349-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,26]],"date-time":"2020-09-26T16:15:18Z","timestamp":1601136918000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11899-016-0349-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10,12]]},"references-count":80,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["349"],"URL":"https:\/\/doi.org\/10.1007\/s11899-016-0349-7","relation":{},"ISSN":["1558-8211","1558-822X"],"issn-type":[{"value":"1558-8211","type":"print"},{"value":"1558-822X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,10,12]]}}}